Seven Eight Capital’s Haemonetics HAE Stock Holding History

Seven Eight Capital’s Portfolio HAE Stock Details HAE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q2	–	Sell	-3,900	Closed	-$389K	–	427
2020 Q1	$389K	Sell	3,900 -3,230	-45%	-$350K	0.1%	260
2019 Q4	$819K	Buy	7,130 +200	+3%	+$24.2K	0.04%	477
2019 Q3	$874K	Buy	+6,930	New	+$880K	0.05%	441
2018 Q4	–	Sell	-9,830	Closed	-$1.13M	–	605
2018 Q3	$1.13M	Sell	9,830 -24,800	-72%	-$2.57M	0.07%	342
2018 Q2	$3.11M	Sell	34,630 -22,270	-39%	-$1.88M	0.22%	143
2018 Q1	$4.16M	Buy	+56,900	New	+$3.9M	0.34%	117

Other funds holding HAE

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return

JSP

Jackson Square Partners Larkspur, California $247M AUM 20.29% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Seven Eight Capital's HAE Position: Q2 2020 in Review

Seven Eight Capital sold out of Haemonetics (HAE) in Q2 2020, closing a stake of 3,900 shares — an estimated $389K sold.

Seven Eight Capital first reported a position in HAE in Q1 2018 and held it in 6 quarters. The position peaked at $4.16M in Q1 2018. 285 funds tracked by Wall St. Rank hold HAE as of Q2 2020.

Seven Eight Capital reported no remaining Haemonetics position as of Q2 2020 after selling out during the quarter.
Seven Eight Capital sold 3,900 Haemonetics shares in Q2 2020, an estimated $389K.
Seven Eight Capital first reported a position in Haemonetics in Q1 2018 and held it in 6 quarters.
Seven Eight Capital's Haemonetics position peaked at $4.16M in Q1 2018.
285 funds tracked by Wall St. Rank held Haemonetics as of Q2 2020.

Based on Seven Eight Capital's 13F filing for Q2 2020, filed 6 Aug 2020.